Simonian Nancy A 4
4 · Syros Pharmaceuticals, Inc. · Filed Apr 2, 2024
Insider Transaction Report
Form 4
Simonian Nancy A
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2024-03-31+39,566→ 145,710 total - Exercise/Conversion
Common Stock
2024-03-31+6,000→ 106,144 total - Tax Payment
Common Stock
2024-04-01$5.12/sh−14,052$71,946→ 131,658 total - Exercise/Conversion
Restricted Stock Units
2024-03-31−6,000→ 12,000 total→ Common Stock (6,000 underlying) - Exercise/Conversion
Restricted Stock Units
2024-03-31−39,566→ 79,134 total→ Common Stock (39,566 underlying)
Footnotes (5)
- [F1]Represents shares of common stock received upon vesting of a restricted stock unit award.
- [F2]Represents shares used to cover tax withholding upon the release of restricted stock units.
- [F3]Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
- [F4]Represents a restricted stock unit award granted on February 15, 2022. These restricted stock units vest in four equal annual installments commencing on March 31, 2023.
- [F5]Represents a restricted stock unit award granted on February 16, 2023. These restricted stock units vest in three equal annual installments commencing on March 31, 2024.